Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

Y0001015

Norfloxacin for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Norfloxacin, 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazino-3-quinolinecarboxylic acid

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C16H18FN3O3
Numero CAS:
70458-96-7
Peso molecolare:
319.33
Numero MDL:
MFCD00079532
Codice UNSPSC:
41116107
ID PubChem:
329831219
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

norfloxacin

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

CCN1C=C(C(O)=O)C(=O)c2cc(F)c(cc12)N3CCNCC3

InChI

1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
OGJPXUAPXNRGGI-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Norfloxacin for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Norfloxacin blocks DNA replication by interfering with an ATP-induced structural transition of DNA complexed with DNA gyrase (topoisomerase).
Mode of action: inhibits bacterial DNA replication
Antimicrobial spectrum: Gram-negative bacteria; less effective against Gram-positive bacteria

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

N1230000

Norfloxacin, European Pharmacopoeia (EP) Reference Standard

N1230010

Norfloxacin impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001301

Norfloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard

1471506

Norfloxacin, United States Pharmacopeia (USP) Reference Standard

1471517

Norfloxacin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1471550

Norfloxacin Related Compound E, United States Pharmacopeia (USP) Reference Standard

1471583

Norfloxacin Related Compound H, United States Pharmacopeia (USP) Reference Standard

1471619

Norfloxacin Related Compound K, United States Pharmacopeia (USP) Reference Standard

PHR1614

Norfloxacin, Pharmaceutical Secondary Standard; Certified Reference Material

BP670

Norfloxacin, British Pharmacopoeia (BP) Reference Standard

PHR2233

Norfloxacin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Nour El-Houda Jlili et al.
Journal of medical microbiology, 63(Pt 2), 195-202 (2013-11-07)
The prevalence of plasmid-mediated quinolone resistance genes [qnr, aac(6')-Ib-cr and qepA] was sought among Enterobacteriaceae strains obtained from the Children's Hospital of Tunis (Tunisia). Non-duplicate isolates (n = 278) with resistance to extended-spectrum cephalosporins and collected in 2003, 2007, 2008 and 2009
G E Stein
The American journal of medicine, 82(6B), 18-21 (1987-06-26)
The pharmacokinetic profile of norfloxacin, an oral fluoroquinolone, is more complex than that of many antibacterial agents. Following administration of a 400-mg dose, peak serum concentrations of 1.5 to 2.0 micrograms/ml are achieved within one to two hours. The drug
C Lee et al.
The American journal of medicine, 82(6B), 27-34 (1987-06-26)
The in vitro spectrum and potency of norfloxacin against both aerobic gram-negative and gram-positive bacteria, its limited activity against anaerobes, and the apparent difficulty organisms have in acquiring resistance to it, have provided a rationale for the clinical development of
A J Schaeffer
European urology, 17 Suppl 1, 19-23 (1990-01-01)
In seven studies of complicated and recurrent urinary tract infections, 285 patients were treated with norfloxacin 400 mg b.i.d. for 7-90 days. The majority of the patients were men, and many were elderly. Underlying diseases included nephrolithiasis, pyelonephritis, prostatism, bacterial
D E Nix et al.
Clinical pharmacy, 6(2), 105-117 (1987-02-01)
The chemistry, mechanism of action, antimicrobial spectrum, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of ciprofloxacin and norfloxacin are reviewed, and mechanisms of antimicrobial resistance and drug and laboratory interactions are described. Norfloxacin is the first antimicrobial in
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.